Abstract library

7 results for "Paclitaxel".
#2690 Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report
Introduction: Sinonasal neuroendocrine carcinomas (SNECs) are a very rare and high-grade malignant epithelial neoplasm that is usually associated with a poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Wang C, ...
#3320 TGF-β increase caspase activation and migration in typical bronchial carcinoids
Introduction: Typical bronchial carcinoids (TBC) are well-differentiated neuroendocrine neoplasms (NEN) whose management can still be very challenging due to reduced sensitivity to therapy. Previous studies have reported TGF-β’s ability to activate mTOR pathway and induce epithelial to mesenchymal transition (EMT). Moreover, preliminary results show an overexpression of TGF-β signalling and caspase activation in TBC.
Conference: 18th Annual ENETS Conference 2021 (2021)
Category: Basic science - Signalling pathways, receptors, biomarkers
Presenting Author: Patricia Borges de Souza
#2964 Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing
Introduction: High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Anna La Salvia
#42 Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas: a Single-Center Experience.
Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Timo Deutschbein
#1040 TIM16 Inhibition Decreases Calcitonin Secretion and Enhances Sensitivity to Paclitaxel in a Human Medullary Thyroid Carcinoma Cells
Introduction: TIM 16 protein is part of the traslocase complex TIM 23 situated in the mitochondrial inner membrane, encoded by the Magmas gene, that is overexpressed in several tumors. Magmas silencing causes a greater sensitivity to apoptotic stimuli. We recently demonstrated that, in a human medullary thyroid carcinoma cell line (TT), compound 5, a TIM 16 inhibitor, was not cytotoxic but enhanced the proapoptotic effects of staurosporine
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Teresa Gagliano
#1294 The Efficacy and Safety of Sunitinib in Heavily Pretreated Patients with NETs. National Cancer Research Center Experience.
Introduction: There was done monocentral trial. 19 pts with progressive well differentiated NETs (G1,G2) were treated with sunitinib
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Anastacia Odintsova
#1778 Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?
Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Jules Derks
Keywords: lcnec, chemotherapy, nec, lung